Association of the frequency of pulmonary infection during the prevaccine period, chronic respiratory failure, pneumococcal polysaccharide vaccine 23, gender and age with the first episode of pulmonary infection or death of any cause
| HR (95% CI) | p Value | |
| Covariates for the risk of the first episode of pulmonary infection | ||
| Pulmonary infection during the prevaccine period | ||
| 1 episode | 3.251* (2.436 to 4.338) | <0.001 |
| >1 episode | 6.480* (4.380 to 9.589) | <0.001 |
| Chronic respiratory failure | 1.767 (1.227 to 2.546) | 0.002 |
| Pneumococcal polysaccharide vaccine 23 vaccination | 1.096 (0.848 to 1.416) | 0.396 |
| Gender | 0.911 (0.712 to 1.166) | 0.457 |
| Age | 0.994 (0.976 to 1.013) | 0.553 |
| Covariates for the risk of death of any cause | ||
| Pulmonary infection during the prevaccine period | ||
| 1 episode | 2.289* (1.380 to 3.797) | 0.001 |
| >1 episode | 3.134* (1.486 to 6.612) | 0.003 |
| Chronic respiratory failure | 2.152 (1.234 to 3.752) | 0.007 |
| Pneumococcal polysaccharide vaccine 23 vaccination | 0.795 (0.499 to 1.264) | 0.332 |
| Gender | 0.340 (0.199 to 0.580) | <0.001 |
| Age | 1.040 (1.008 to 1.072) | 0.014 |
* HR was estimated in relation to the case of outpatients with no episode of pulmonary infection during the prevaccine period.